Simvastatin prevents lipopolysaccharide-induced septic shock in rats

被引:0
作者
Li Yu
Xing-wen Da
Xiao-ling Wu
Ao-di He
Ding Long
机构
[1] Huazhong University of Science and Technology,Intensive Care Unit, Wuhan Central Hospital, Tongji Medical College
[2] Huazhong University of Science and Technology,Department of Pharmacology, School of Basic Medicine, Tongji Medical College
来源
Journal of Huazhong University of Science and Technology [Medical Sciences] | 2017年 / 37卷
关键词
septic shock; lipopolysaccharide; urokinase-type plasminogen activator; plasminogen activator inhibitor-1; simvastatin;
D O I
暂无
中图分类号
学科分类号
摘要
Simvastatin is a hypolipidemic drug that inhibits hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase to control elevated cholesterol, or hypercholesterolemia. Previous studies have shown that simvastatin may attenuate inflammation in ischemia-reperfusion injury and sepsis. Herein, we hypothesized that simvastatin may prevent rats from lipopolysaccharide (LPS)-induced septic shock. In our study, rats were divided into a saline group, an LPS group and an LPS plus simvastatin group. Male Sprague-Dawley (SD) rats were pretreated with simvastatin (1 mg/kg) for 30 min before the addition of LPS (8 mg/kg), with variations in left ventricular pressure recorded throughout. Ninety min after LPS injection, whole blood was collected from the inferior vena cava, and neutrophils were separated from the whole blood using separating medium. The neutrophils were then lysed for Western blotting to detect the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1). In addition, mesentery microcirculations of inlet diameter, outlet diameter and blood flow rate were measured in all three groups. The results indicated that simvastatin significantly promoted heart systolic function and increased the level of uPA while simultaneously inhibited the expression of PAI-1 as compared with LPS group. Moreover, simvastatin reversed the LPS-induced inhibition of mesentery microcirculation. Taken together, it was suggested that simvastatin can effectively protect the rats from LPS-induced septic shock.
引用
收藏
页码:226 / 230
页数:4
相关论文
共 98 条
[1]  
Rudiger A(2013)The heart in sepsis: from basic mechanisms to clinical management Curr Vasc Pharmacol 11 187-195
[2]  
Singer M(2013)Microcirculation in sepsis: new perspectives Curr Vasc Pharmacol 11 161-169
[3]  
Hernandez G(1997)Granules of the human neutrophilic polymorphonuclear leukocyte Blood 89 3503-3521
[4]  
Bruhn A(2014)The heterogenic properties of monocytes/macrophages and neutrophils in inflammatory response in diabetes Life Sci 116 59-66
[5]  
Ince C(2000)A review of septic shock Am Surg 66 22-29
[6]  
Borregaard N(2004)uPA and uPAR in fibrinolysis, immunity and pathology Trends Immunol 25 450-455
[7]  
Cowland JB(2006)Evaluation of haemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections Thromb Haemost 95 282-287
[8]  
Rao XQ(2012)PAI-1, progress in understanding the clinical problem and its aetiology Brit J Haematol 157 291-298
[9]  
Zhong JX(2013)Biomarkers of endothelial cell activation in early sepsis Shock 39 427-432
[10]  
Sun QH(2010)4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study Crit Care 14 R279-175